Olimel N12

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin, the active ingredient in Olimel N12, is a mixture of essential and non‑essential amino acids presented as a sterile powder for intravenous use. It is intended for nutritional support in patients requiring parenteral amino acid supplementation.

GNH USA supplies Olimel N12 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Olimel N12 provides nutritional amino acid support for conditions where protein synthesis is compromised.

- Post‑operative recovery: helps meet increased protein needs during healing. - Severe trauma or burns: supports tissue repair and nitrogen balance. - Critical illness or intensive care: contributes to maintaining lean body mass in patients receiving total parenteral nutrition. - Chronic renal failure on dialysis: supplies essential amino acids while limiting nitrogen waste. - Malnutrition in oncology patients: assists in preserving muscle mass during chemotherapy. - Liver disease‑related catabolism: provides balanced amino acids for patients with hepatic insufficiency.

Adverse reactions are reported infrequently but may occur with any intravenous amino acid formulation.

Common Side Effects: - Mild fever or chills: transient rise in body temperature after infusion. - Local irritation: redness or discomfort at the infusion site. - Nausea: occasional feeling of queasiness during or after administration. - Headache: mild headache reported by some patients. - Elevated serum electrolytes: temporary changes in potassium or phosphate levels.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Hyperammonemia: excessive ammonia accumulation leading to neurological symptoms. - Metabolic acidosis: significant shift in blood pH requiring correction. - Thrombophlebitis: inflammation of a vein with clot formation at the infusion site. - Renal dysfunction: worsening kidney function in susceptible individuals.

When administering Olimel N12, clinicians should consider patient‑specific factors and follow best practice guidelines.

- Assess renal function: adjust infusion rate in patients with impaired kidneys. - Monitor electrolytes: check serum potassium, phosphate and calcium during therapy. - Evaluate liver function: watch for signs of hyperammonemia. - Observe for allergic reactions: be prepared to manage anaphylaxis. - Use aseptic technique: maintain sterility to prevent contamination. - Store at 2-8°C: keep refrigerated, protect from light and do not freeze the vial or powder.

Olimel N12 may interact with other intravenous solutions and medications administered concurrently.

Major Interactions (Avoid): - High‑dose potassium chloride: risk of hyperkalemia when combined with amino acid solutions. - Acidic IV fluids: may cause precipitation of calcium salts in the mixture.

Moderate Interactions (Monitor Closely): - Loop diuretics: can amplify electrolyte shifts, requiring closer monitoring. - Anticoagulants: altered plasma protein binding may affect drug levels. - Insulin therapy: amino acids stimulate insulin release, potentially affecting glucose control. - Hepatotoxic drugs: increased risk of hyperammonemia when combined with liver‑targeting agents. - Other parenteral nutrition ​​  ​  ​   ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​